United States

Profile: AngioDynamics Inc (ANGO.O)

ANGO.O on Nasdaq

3:06pm EDT
Change (% chg)

$-0.12 (-0.76%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

AngioDynamics, Inc., incorporated on July 30, 1992, designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery.

Peripheral Vascular Products

The Company's Peripheral Vascular products include fluid management, venous, thrombus management, as well as other core products. The Company's Fluid Management product offering includes the NAMIC Fluid Management portfolio. The NAMIC product line provides devices that help in the diagnosis and treatment of cardiovascular and peripheral vascular disease. The NAMIC product line includes an offering of manifolds, contrast management systems, closed fluid systems, guide wires, disposable transducers and interventional accessories. These devices are utilized together and allow clinicians to aspirate or inject contrast, saline, remove waste and monitor invasive blood pressures across the procedure.

The Company's venous products focus on the treatment of varicose veins and consist of its VenaCure EVLT laser system, Asclera (polidocanol) injection and Sotradecol. The Company's VenaCure EVLT laser system products are used in endovascular laser procedures to treat superficial venous disease (varicose veins). With its VenaCure EVLT laser system, laser energy is used to stop the reflux by ablating, or collapsing and destroying the affected vein. The body subsequently re-routes the blood to other healthy veins. Its products are sold as a system that includes diode laser hardware with its family of disposable laser fiber components, training and marketing materials. The disposable components in the system include a laser fiber system featuring its NeverTouch gold-tip technology, an access sheath, access wires and needles. The procedure kits come in a range of lengths and configurations to accommodate varied patient anatomies. The Company's VenaCure EVLT 1470 nanometer wavelength laser allows customers to heat the vein wall using lower power settings thereby reducing the risk of collateral damage. Asclera (polidocanol) injection is a sclerosing drug that the Company distributes through a global agreement with the manufacturer and their distributor. Asclera is used for sclerotherapy to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity. Sotradecol is indicated for non-surgical treatment of small, uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.

The Company's thrombus management product offerings include its AngioVac and thrombolytic products. The Company's AngioVac venous drainage system includes a venous drainage cannula and cardiopulmonary bypass circuit. The AngioVac devices are for use with other manufacturer's off-the-shelf pump, filter and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The cannula is indicated for use as a venous drainage cannula and for removal of fresh, soft thrombi or emboli during extracorporeal bypass. The cardiopulmonary bypass circuit is indicated for use in procedures requiring extracorporeal circulatory support for periods of over six hours. The AngioVac venous drainage cannula is a 22F coil-reinforced cannula designed with a balloon actuated, expandable funnel shaped distal tip. The funnel shaped tip enhances venous drainage flow when the balloon is inflated, prevents clogging of the cannula with commonly encountered undesirable intravascular material, and facilitates en bloc removal of such extraneous material. Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins and surgical bypass grafts.

The Company's other core peripheral vascular products include angiographic products and accessories, drainage, micro access and other products. Angiographic products and accessories are used during peripheral vascular interventional procedures. Drainage products percutaneously drain abscesses and other fluid pockets. The Company's line of drainage products, The Total Abscession Family of Drainage Catheters, consists of its Total Abscession General, Biliary and Nephrostomy drainage catheters. These products feature its soft shaft with Blue Silk finish for a comfortable patient fit. The Company's Total Abscession drainage catheters feature a tamper-resistant locking mechanism called the Vault, which fixes the pigtail and prevents tampering or accidental removal. Its Micro Access sets provide interventional physicians an introducer system for minimally-invasive procedures. Its Micro Access product line provides physicians with the means to build a custom set from the selection of configurations available, including over four wires in two different lengths, seven needle options and three sheath dilator options.

Vascular Access

Image-guided vascular access (IGVA) involves the use of advanced imaging equipment to guide the placement of catheters that deliver primarily short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system. IGVA procedures include the placement of peripherally inserted central catheter (PICC) lines, implantable ports and central venous catheters (CVCs).

The Company's BioFlo products use Endexo technology into the manufacturing and design of its Vascular Access products. Endexo is a fluorine-based additive that creates a non-eluting (permanent), non-heparin-based catheter material that is designed to reduce thrombus accumulation and platelet adhesion to all surfaces of the catheter. A PICC is a long thin catheter that is inserted into a peripheral vein in the upper arm, and advanced until the catheter tip terminates in a large vein in the chest near the heart to obtain intravenous access. PICCs can be used for prolonged periods of time and provide an alternative to central venous catheters. The Company's PICC product offerings include BioFlo PICC, which is a power injectable PICC available that uses Endexo Technology into the manufacturing and design of the catheter; Xcela PICC, which is designed to deliver the power injection flow rates required for contrast-enhanced computed tomography (CTs) compatible with approximately 325 pectus severity index (psi) CT injections, and PASV Valve Technology, which is designed to automatically resist backflow and reduce blood reflux that could lead to catheter-related complications.

The Company's ports are used primarily in systemic or regional short and long-term cancer treatment protocols that require frequent infusions of concentrated or toxic medications, such as chemotherapy agents, antibiotics or analgesics, and frequent blood samplings. The Company's port products include BioFlo Port, SmartPort, Vortex, PASV Valve Technology and LifeGuard. The Company markets a line of dialysis products that provide short and long-term vascular access for dialysis patients. The Company offers a range of dialysis catheters, including BioFlo and DuraMax.

Oncology/Surgery Products

The Company's Oncology/Surgery product offerings include its microwave ablation products, such as radiofrequency ablation (RFA) and NanoKnife product lines. The Company's Acculis microwave tissue ablation (MTA) System complements the range of ablative technologies it offers. When configured for use with the Accu2i pMTA Applicators, it includes the Sulis VpMTA Generator, optional MTA Temperature Probes, acculis local control station (LCS) and Accu2i pMTA Applicators. Designed for physicians trained in image-guided ablation procedures, intraoperative ultrasound and/or CT guided needle placement, the system is used for thermal coagulation of soft tissue. The radiofrequency ablation (RFA) products use radiofrequency energy to provide a minimally invasive approach to ablating solid cancerous or benign tumors. Its system delivers radiofrequency energy to raise the temperature of cells above 45 to 50 degree Celsius, causing cellular death. The RFA system consists of a radiofrequency generator and a family of disposable devices. The Company also markets the Habib 4X resection device.

The NanoKnife Ablation System is for the surgical ablation of soft tissue. The NanoKnife Ablation System utilizes low energy direct current (LEDC) electrical pulses to permanently open pores in target cell membranes. These permanent pores or nano-scale defects in the cell membranes result in cell death. The treated tissue is then removed by the body's natural processes in a matter of weeks, mimicking natural cell death. The NanoKnife Ablation System consists of two components: a LEDC generator and needle-like electrode probes. Up to six electrode probes can be placed into or around the targeted soft tissue. Once the probes are in place, the user enters the appropriate parameters for voltage, number of pulses, interval between pulses and the pulse length into the generator user interface. The generator then delivers a series of short electric pulses between each electrode probe. The energy delivery is hyperechoic and can be monitored under real-time ultrasound.

The Company competes with Boston Scientific Corporation, Cook Medical, C.R. Bard, Medical Components, Inc., TeleFlex Medical, Smiths Group plc, Vascular Solutions, Medtronic, Merit Medical, Terumo Medical Corporation, Johnson and Johnson, and Total Vein Systems.

Company Address

AngioDynamics Inc

14 Plaza Dr
LATHAM   NY   12110-2166
P: +1518.7981215
F: +1518.7951401

Company Web Links